These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 19809306

  • 1. Plasma thrombomodulin activity, tissue factor activity and high levels of circulating procoagulant phospholipid as prognostic factors for acute myocardial infarction.
    Van Dreden P, Rousseau A, Savoure A, Lenormand B, Fontaine S, Vasse M.
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):635-41. PubMed ID: 19809306
    [Abstract] [Full Text] [Related]

  • 2. Imbalance of plasminogen activator inhibitor-I/ tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction.
    Saigo M, Abe S, Ogawa M, Yamashita T, Biro S, Minagoe S, Maruyama I, Tei C.
    Thromb Haemost; 2001 Nov; 86(5):1197-203. PubMed ID: 11816707
    [Abstract] [Full Text] [Related]

  • 3. Changes in plasma C-reactive protein and hemostatic factors prior to and after a first myocardial infarction with a median follow-up time of 8 years.
    Thøgersen AM, Nilsson TK, Weinehall L, Boman K, Eliasson M, Hallmans G, Jansson JH.
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):340-6. PubMed ID: 19357504
    [Abstract] [Full Text] [Related]

  • 4. Elevated circulating soluble thrombomodulin activity, tissue factor activity and circulating procoagulant phospholipids: new and useful markers for pre-eclampsia?
    Rousseau A, Favier R, Van Dreden P.
    Eur J Obstet Gynecol Reprod Biol; 2009 Sep; 146(1):46-9. PubMed ID: 19564071
    [Abstract] [Full Text] [Related]

  • 5. Plasma thrombomodulin, fibrinogen, and activity of tissue factor as risk factors for acute cerebral infarction.
    Zhang X, Hu Y, Hong M, Guo T, Wei W, Song S.
    Am J Clin Pathol; 2007 Aug; 128(2):287-92. PubMed ID: 17638664
    [Abstract] [Full Text] [Related]

  • 6. Von Willebrand factor, plasminogen activator inhibitor-1 and C-reactive protein are markers of thrombolytic efficacy in acute myocardial infarction.
    Andreotti F, Hackett DR, Haider AW, Roncaglioni MC, Davies GJ, Beacham JL, Kluft C, Maseri A.
    Thromb Haemost; 1992 Dec 07; 68(6):678-82. PubMed ID: 1287882
    [Abstract] [Full Text] [Related]

  • 7. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C.
    Clin Endocrinol (Oxf); 2006 Mar 07; 64(3):323-9. PubMed ID: 16487444
    [Abstract] [Full Text] [Related]

  • 8. Do plasma biomarkers of coagulation and fibrinolysis differ between patients who have experienced an acute myocardial infarction versus stable exertional angina?
    Itakura H, Sobel BE, Boothroyd D, Leung LL, Iribarren C, Go AS, Fortmann SP, Quertermous T, Hlatky MA, Atherosclerotic Disease, Vascular Function and Genetic Epidemiology Advance (ADVANCE) Study.
    Am Heart J; 2007 Dec 07; 154(6):1059-64. PubMed ID: 18035075
    [Abstract] [Full Text] [Related]

  • 9. Lower tissue factor inhibition in patients with ST segment elevation than in patients with non ST elevation acute myocardial infarction.
    Figueras J, Monasterio J, Lidón RM, Sambola A, Garcia-Dorado D.
    Thromb Res; 2012 Sep 07; 130(3):458-62. PubMed ID: 22424853
    [Abstract] [Full Text] [Related]

  • 10. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
    Wada H, Mori Y, Okabayashi K, Gabazza EC, Kushiya F, Watanabe M, Nishikawa M, Shiku H, Nobori T.
    Am J Hematol; 2003 Jan 07; 72(1):1-7. PubMed ID: 12508260
    [Abstract] [Full Text] [Related]

  • 11. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation.
    Cugno M, Mari D, Meroni PL, Gronda E, Vicari F, Frigerio M, Coppola R, Bottasso B, Borghi MO, Gregorini L.
    Br J Haematol; 2004 Jul 07; 126(1):85-92. PubMed ID: 15198737
    [Abstract] [Full Text] [Related]

  • 12. Normalisation of tissue factor pathway inhibitor activity after glycaemic control optimisation in type 1 diabetic patients.
    Rigla M, Mateo J, Fontcuberta J, Souto JC, de Leiva A, Pérez A.
    Thromb Haemost; 2000 Aug 07; 84(2):223-7. PubMed ID: 10959693
    [Abstract] [Full Text] [Related]

  • 13. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF.
    Bellucci S, Ignatova E, Jaillet N, Boffa MC.
    Thromb Haemost; 1993 Nov 15; 70(5):736-42. PubMed ID: 8128427
    [Abstract] [Full Text] [Related]

  • 14. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes.
    Chong AY, Freestone B, Patel J, Lim HS, Hughes E, Blann AD, Lip GY.
    Am J Cardiol; 2006 Mar 01; 97(5):671-5. PubMed ID: 16490435
    [Abstract] [Full Text] [Related]

  • 15. [Value of plasma tissue factor, tissue factor pathway inhibitor and factor VII assessments in patients with acute myocardial and cerebral infarction].
    Xiong SL, Wang Q, Zheng L, Li JL, Wen ZB, He SL.
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Dec 01; 27(12):1821-3. PubMed ID: 18158992
    [Abstract] [Full Text] [Related]

  • 16. [Tissue plasminogen activator as a prognostic factor in myocardial infarct patients].
    Fernández Abellán P, Marín Ortuño F, Marco Vera P, Luján Martínez J.
    Rev Clin Esp; 1999 Apr 01; 199(4):215-7. PubMed ID: 10364793
    [Abstract] [Full Text] [Related]

  • 17. Increased levels of tissue factor activity and procoagulant phospholipids during treatment of children with acute lymphoblastic leukaemia.
    Schneider P, Van Dreden P, Rousseau A, Kassim Y, Legrand E, Vannier JP, Vasse M.
    Br J Haematol; 2010 Feb 01; 148(4):582-92. PubMed ID: 19874310
    [Abstract] [Full Text] [Related]

  • 18. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S.
    Dan Med Bull; 1993 Sep 01; 40(4):383-408. PubMed ID: 8222763
    [Abstract] [Full Text] [Related]

  • 19. Comparative evaluation of Tissue factor and Thrombomodulin activity changes during normal and idiopathic early and late foetal loss: the cause of hypercoagulability?
    Van Dreden P, Woodhams B, Rousseau A, Favier M, Favier R.
    Thromb Res; 2012 Jun 01; 129(6):787-92. PubMed ID: 21880353
    [Abstract] [Full Text] [Related]

  • 20. Tissue factor pathway inhibitor, natural coagulation inhibitors and hemostatic activation markers in patients with acute coronary syndromes.
    Al-Nozha MM, Abdel-Gader AG, Arafah MR, Al-Maatouq MA, Al-Shahid MS, Al-Harthi SS, Khan NB, Abdullah MA.
    Saudi Med J; 2005 Jun 01; 26(6):937-42. PubMed ID: 15983678
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.